166 related articles for article (PubMed ID: 29069221)
1. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
Shen JC; Zhang YC; Zhao MF
Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221
[TBL] [Abstract][Full Text] [Related]
2. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice.
Chai X; Li D; Cao X; Zhang Y; Mu J; Lu W; Xiao X; Li C; Meng J; Chen J; Li Q; Wang J; Meng A; Zhao M
Sci Rep; 2015 May; 5():10181. PubMed ID: 25970748
[TBL] [Abstract][Full Text] [Related]
3. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
[TBL] [Abstract][Full Text] [Related]
4. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
[TBL] [Abstract][Full Text] [Related]
5. [Effects of oxidative stress on hematopoiesis of hematopoietic stem and progenitor cells with iron overload].
Xie F; Zhao MF; Zhu HB; Lu WY; Xu XN; Xiao X; Mu J; Liu PJ; Li YM
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(46):3284-8. PubMed ID: 22333152
[TBL] [Abstract][Full Text] [Related]
6. Effects of iron overload on the bone marrow microenvironment in mice.
Zhang Y; Zhai W; Zhao M; Li D; Chai X; Cao X; Meng J; Chen J; Xiao X; Li Q; Mu J; Shen J; Meng A
PLoS One; 2015; 10(3):e0120219. PubMed ID: 25774923
[TBL] [Abstract][Full Text] [Related]
7. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
[TBL] [Abstract][Full Text] [Related]
8. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of an mouse model of iron-overload and its impact on bone marrow hematopoiesis].
Chai X; Zhao MF; Li DG; Meng JX; Lu WY; Mu J; Meng AM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Oct; 35(5):547-52. PubMed ID: 24183045
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes.
Chen J; Lu WY; Zhao MF; Cao XL; Jiang YY; Jin X; Xu P; Yuan TT; Zhang YC; Chai X; Meng JX; Li Q; Xiao X; Mu J; Li DG; Qi AP
Ann Hematol; 2017 Jul; 96(7):1085-1095. PubMed ID: 28421266
[TBL] [Abstract][Full Text] [Related]
14. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
16. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients.
Lu W; Zhao M; Rajbhandary S; Xie F; Chai X; Mu J; Meng J; Liu Y; Jiang Y; Xu X; Meng A
Eur J Haematol; 2013 Sep; 91(3):249-261. PubMed ID: 23772810
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
Pullarkat V; Sehgal A; Li L; Meng Z; Lin A; Forman S; Bhatia R
Leuk Res; 2012 Aug; 36(8):966-73. PubMed ID: 22502920
[TBL] [Abstract][Full Text] [Related]
18. [Effects and mechanism of iron overload on hematopoiesis in mice with bone marrow injury].
Chai X; Zhao M; Li D; Zhang Y; Lu W; Cao X; Meng J; You Q; Meng A
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):1000-4. PubMed ID: 25417878
[TBL] [Abstract][Full Text] [Related]
19. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
Adel RM; Lotfy RA; Darwish AS; Amer AS
J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
